论文部分内容阅读
恶性嗜铬细胞瘤及其转移病灶对常规的化疗及体外放疗的效果不佳,~(131)I-MIBG(~(131)I-间位碘代苄胍)是抗神经元的阻断剂,能被具有神经分泌颗粒的所有肿瘤如嗜铬细胞瘤、恶性嗜铬细胞瘤及其转移灶所摄取,并能浓集于甲状腺髓样癌组织内,使~(131)I-MIBG在肿瘤的放射性活度是肝的680倍。同时,~(131)I-MIBG释放的β射线使肿瘤受到较大量的辐射,使肿瘤的活性受到抑制和破坏、减轻症状、降低血压、缩小瘤体。因此,~(131)I-MIBG治疗恶性嗜铬细胞瘤及神经母细胞瘤已广泛应用于临床。本文用~(131)I-MIBG治疗7例恶性嗜铬细胞瘤病人,治疗效果显著,现报道如下。
Malignant pheochromocytoma and its metastatic lesions are not effective on conventional chemotherapy and in vitro radiotherapy. 131I-MIBG (~ (131) I-metaiodobenzylguanidine) is an anti-neuronal blocker , Can be taken up by all tumors with neurosecretory granules such as pheochromocytoma, malignant pheochromocytoma and their metastases, and can be concentrated in medullary thyroid carcinoma tissues to make ~ (131) I-MIBG in the tumor The radioactivity is 680 times that of the liver. At the same time, β-rays released by ~ (131) I-MIBG cause the tumor to receive a larger amount of radiation, which inhibits and destroys the tumor activity, alleviates the symptoms, reduces the blood pressure and reduces the tumor volume. Therefore, ~ (131) I-MIBG treatment of malignant pheochromocytoma and neuroblastoma has been widely used in clinical. This article with ~ (131) I-MIBG treatment of 7 patients with malignant pheochromocytoma, the treatment effect is remarkable, are reported below.